GC Biopharma Corp.'s latest marketcap:
As of 07/30/2025, GC Biopharma Corp.'s market capitalization has reached $1.19 B. According to our data, GC Biopharma Corp. is the 8807th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 1.19 B |
| Revenue (ttm) | 1.23 B |
| Net Income (ttm) | 20.68 M |
| Shares Out | 11.41 M |
| EPS (ttm) | 1.81 |
| Forward PE | 35.56 |
| Ex-Dividend Date | 12/27/2024 |
| Earnings Date | 08/14/2025 |
GC Biopharma Corp.'s yearly market capitalization.
| Date | Market Cap(₩) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 07/30/2025 | ₩1.66 T | $1.19 B | -18.94% | 8807 |
| 12/30/2024 | ₩2.05 T | $1.37 B | 43.03% | 7244 |
| 12/28/2023 | ₩1.43 T | $1.1 B | -3.09% | 8134 |
| 12/29/2022 | ₩1.48 T | $1.17 B | -40.6% | 7527 |
| 12/30/2021 | ₩2.49 T | $2.09 B | -46.31% | 5967 |
| 12/30/2020 | ₩4.63 T | $4.26 B | 206.42% | 3214 |
| 12/30/2019 | ₩1.51 T | $1.3 B | -2.57% | 5865 |
| 12/28/2018 | ₩1.55 T | $1.38 B | -39.82% | 5050 |
| 12/28/2017 | ₩2.58 T | $2.4 B | 42.08% | 4060 |
| 12/29/2016 | ₩1.82 T | $1.49 B | -14.21% | 4903 |
Company Profile
About GC Biopharma Corp.
GC Biopharma Corp. is a biopharmaceutical company specializing in the development and sale of pharmaceutical drugs in South Korea and internationally. Founded in 1967 and headquartered in Yongin-Si, South Korea, the company operates as a subsidiary of Green Cross Holdings Corporation.
Key Products & Offerings
- Over-the-Counter Drugs:
- Acustop Cataplasma (Analgesic & anti-inflammatory)
- Kenhancer Plaster (Anti-inflammatory)
- Zenol Cool Type & Zenol Mild Hot Type (Pain relief & anti-inflammatory)
- Prescription & Specialty Medications:
- Albumin-GCC Injection (Hypoalbuminemia & shock treatment)
- Antithrombin-III (AT-III) Injection (Hereditary deficiency)
- Facnyne Injection (Hemophilia B)
- Fibrinogen (Hypofibrinogenemia treatment)
- Gamma Globulin (Hypogammaglobulinemia treatment)
- GCFLU Quadrivalent & GC FLU Pre-filled Syringe (Influenza prevention)
- GreenGene F Injection (Hemophilia A hemostasis)
- Greenplast Q (Tissue sealing & wound closure)
- Green-VIII Injection (Hemophilia A coagulation support)
- Hepabig Injection (Hepatitis B treatment)
- Hunterase (Hunter syndrome therapy)
- I.V. Hepabig Injection (Hepatitis B recurrence prevention)
- Shinbaro (Anti-inflammatory & osteoarthritis relief)
- Varicella Vaccine-GCC Injection (Varicella prophylaxis)
Research & Collaborations
The company has an active R&D partnership with Novelty Nobility to develop antibody-based therapeutics for geographic atrophy, expanding its innovative treatment pipeline.
Corporate Background
With a legacy since 1967, GC Biopharma Corp. continues to advance healthcare solutions globally, backed by its parent company, Green Cross Holdings Corporation.
Frequently Asked Questions
-
What is GC Biopharma Corp.'s (KRX-006280) current market cap?As of 07/30/2025, GC Biopharma Corp. (including the parent company, if applicable) has an estimated market capitalization of $1.19 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does GC Biopharma Corp. (KRX-006280) rank globally by market cap?GC Biopharma Corp. global market capitalization ranking is approximately 8807 as of 07/30/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.